Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 7/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30602946 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1PPARAALOX5LOXL2 | |
| SCHEMBL9153184 | 0.91 | SMN1; SMN2 (0.82) | SMN1; SMN2NPSR1PPARAALOX5LOXL2 | |
| SCHEMBL6662857 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2NPSR1PPARAKEAP1 | |
| SCHEMBL8523609 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2NPSR1PPARAALOX5LOXL2 | |
| SCHEMBL30423143 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2NPSR1PPARAALOX5TMEM97 | |
| SCHEMBL9622398 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2NPSR1PPARAALOX5TMEM97 | |
| SCHEMBL4051451 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2NPSR1PPARAALOX5 | |
| SCHEMBL4051455 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2NPSR1PPARAALOX5 | |
| SCHEMBL4051453 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2NPSR1PPARAALOX5 | |
| SCHEMBL14327114 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2NPSR1PPARAKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59053475-A | — | — | None | — | — | JP | disclosed |
| JP-56140986-A | — | — | None | — | — | JP | disclosed |
| CN-111454281-B | Merocyanine compound, dye for biomolecule labeling, kit and contrast agent composition containing same | SFC株式会社 | 2024-04-09 | — | — | CN | disclosed |
| CN-116926578-A | Method for synthesizing heteroaryl thiophenol | 新疆大学 | 2023-10-24 | — | — | CN | disclosed |
| CN-111454281-A | Merocyanine compound, dye for biomolecule labeling comprising same, kit, and contrast agent composition | SFC株式会社 | 2020-07-28 | — | — | CN | disclosed |
| CN-107304219-B | Merocyanine compound, dye for biomolecule labeling comprising same, kit, and contrast agent composition | SFC株式会社 | 2020-05-15 | — | — | CN | disclosed |
| EP-2822945-B1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | COMPOUND HANDLING B V (NL) | 2019-06-19 | — | — | EP | disclosed |
| US-10071987-B2 | Aminomethylene pyrazolones with therapeutic activity | COMPOUND HANDLING B.V. (NL) | 2018-09-11 | — | — | US | disclosed |
| US-10029996-B2 | Class of cyano-substituted asymmetric cyanine dyes, synthesizing method and application thereof | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2018-07-24 | — | — | US | disclosed |
| US-9969887-B2 | Merocyanine-based compounds, and dyes, kits and contrast medium compositions for labelling biomolecules comprising the same | SFC CO., LTD. (KR) | 2018-05-15 | — | — | US | disclosed |
| EP-0467155-B1 | Blue spectral sensitizers for non-tabular silver halide elements | DU PONT (US) | 1995-02-22 | — | — | EP | disclosed |
| US-5108887-A | Zeromethine merocyanine dyes as J-aggregating spectral sensitizers for tabular emulsions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
| US-5102781-A | Used for radiographic elements designed for exposure to intensifying screens | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-07 | — | — | US | disclosed |
| EP-0467155-A1 | Blue spectral sensitizers for non-tabular silver halide elements | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-22 | — | — | EP | disclosed |
| US-5053408-A | Cardiovascular disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0393574-A2 | Hexitol derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| JP-S5953475-A | PREPARATION OF BENZOTHIAZOLONE DERIVATIVE | FUJISAWA PHARMACEUT CO LTD | 1984-03-28 | — | — | JP | disclosed |
| EP-0055428-B1 | BIS-(3-SULFOPROPYL)ETHERS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ALKYLATING AGENTS FOR ORGANIC BASES | Agfa-Gevaert AG (DE) | 1984-03-14 | — | — | EP | disclosed |
| EP-0055428-A1 | Bis-(3-sulfopropyl)ethers, process for their preparation and their use as alkylating agents for organic bases | Agfa-Gevaert AG (DE) | 1982-07-07 | — | — | EP | disclosed |
| JP-S56140986-A | PRODUCTION OF 5-CHLORO-3- 4- 2-HYDROXYETHYL -1-PIPERAZINYL - CARBOMETHYL-2-BENZOTHIAZOLINE OR ITS SALT AND INTERMEDIATE | HAMARI YAKUHIN KOGYO KK | 1981-11-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029996-B2 | Class of cyano-substituted asymmetric cyanine dyes, synthesizing method and application thereof | HCCS, MKI67, MB | SMN1; SMN2 1982/4885NPSR1 4262/4885PPARA 4348/4885 |
| US-10071987-B2 | Aminomethylene pyrazolones with therapeutic activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 | SMN1; SMN2 2217/4885NPSR1 2175/4885PPARA 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.